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Identifying subjects who are at risk for SCD and stratifying them correctly into low or high-
risk groups is the holy grail of Cardiology. While imaging shows a lot of promise, it is
plagued by the fact that most SCD occurs in relatively healthy subjects, a massive group
who would not ordinarily be subjected to imaging. Left ventricular ejection fraction (LVEF)
currently is our primary parameter for risk stratification for sudden cardiac death but is a
poor marker with low sensitivity and specificity. Current data shows that sophisticated
imaging with techniques, mainly Cardiac magnetic resonance Imaging (CMR), have the
potential to identify novel high-risk markers underlying SCD, beyond ejection fraction.
Imaging seems to further refine risk in patients with low LVEF as well as in those with
normal EF; this is a major strength of advanced imaging. Clinical application has been slow
and not fully prime time. It is important to remember that while promising, imaging
techniques including CMR, have not been tested in rigorous prospective studies and thus
have not as yet replaced EF as the gatekeeper to ICD implantation.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Sudden cardiac death (SCD), unexpected cardiac death usually
within an hour after the onset of symptoms, remains a major
health problem.1 Estimates in the US range widely but it ac-
counts for approximately 50% of deaths from cardiovascular
diseases.2 Predicting who will die suddenly from ventricular
arrhythmias is extremely difficult and predicting sudden
death, proximate to the event, is nearly impossible with cur-
rent technology. Presence of structural heart disease,4.
handrashekhar).
2013, Cardiological Societespecially LV dysfunction, is predictive of risk for long term
SCD. Unfortunately, the majority of patients presenting with
SCD often have normal LV function and death is often the first
symptom of heart disease.3 Risk stratifying for SCD is thus a
challenge e the deaths are by definition sudden and more
importantly, unexpected in most cases; worsening heart dis-
ease is a strong predictor of SCD, but this becomes less useful
since most of the deaths occur in subjects with no heart dis-
ease. Current indices to risk stratify SCD are thus sub optimal
and we urgently need newer and novel methods to identify
and characterize substrate that can trigger SCD. Imaging cany of India. All rights reserved.
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us refine our thinking about who will have sudden cardiac
death. Traditional cardiac imaging identifies increased risk of
SCDmainly via its ability to show structural substrates like EF,
hypertrophy, scar and scar heterogeneity.4 Newer imaging
modalities, especially molecular imaging, might allow us to
image channels and interstitial connections and even con-
duction itself but these are in the research arena at this time.
Imaging can also assess triggers that impart increased risk of
ventricular arrhythmias (e.g. cardiac autonomic abnormality,
pattern of innervation, etc). In this article, we will briefly re-
view the role of multi-modality imaging techniques in iden-
tifying patients at risk for sudden cardiac death and illustrate
how imaging aids in therapeutic decision making in disorders
known to lead to SCD. Purely research methodologies and
those not freely available like molecular imaging techniques
will not be discussed in this review.
The etiology of SCD differs depending on the age group
studied. In adults, SCD is most often seen over a background of
coronary artery disease.1,4 Non-ischemic cardiomyopathies
account for 10e15%,whereas other cardiac disorders, including
valvular heart disease, congenital heart defects and channelo-
pathies, account for the remainder. Our current, albeit incom-
plete, understanding of the mechanism of SCD postulates a
complex interaction betweenmultiple factors including genetic
predisposition (e.g. channelopathies), anatomic substrates (e.g.
coronary artery disease, coronary artery anomalies,myocardial
scar), and functional triggers (suchas ischemia, neurohormonal
factors, metabolic perturbations as well as, hemodynamic
changes). Most of the time, the final common pathway is pre-
sumed to be a fatal ventricular arrhythmia; ventricular fibrilla-
tion is the first recorded rhythm in 75e80% of patients
presentingwith sudden cardiovascular collapse, although,with
better monitoring5 and change in therapies,6 a bradycardiac
death is being recognized more often now than before. More-
over, our ability to diagnose the etiology of SCD is also sub
optimal and a significant proportion of patients of presumed to
have arrhythmic SCD end up to have other non-arrhythmic
causes.7 Thus imaging, while promising, should be considered
in light of SCDetiologies, current successful therapies that arose
fromclinical trials that did not need complex stratificationwith
advanced imagingandfinally, its applicability to thegeneral low
risk population where SCD is the commonest.2. Imaging targets in sudden cardiac death
While a traditional review can addressmultimodality imaging
in each of the cardiac conditions associated with SCD, all
current imaging seems to address only a few mechanistic
targets, namely structure of the heart, its function, presence
of scar and in a few cases, state of the cardiac autonomic
system. Vulnerable plaque and ischemia often underlie SCD
and are excellent targets for imaging e in fact, CMR seems to
be identifying sub clinical myocardial infarction in many
cases presenting with unexplained SCD both in life (SCD
survivors) and in death (post mortem) CMR forensics e.8
However, ischemia and evaluation for vulnerable plaque is
not usually a directly proximate stratifying marker for SCD.
Noninvasive risk-stratification techniques for identifyingpatients with coronary artery disease at risk for SCD also do
not emphasize these as markers as primary targets.4
2.1. Ejection fraction (EF)
ReducedEF is themostwidely usedmarker for increased risk of
SCD in patients with ischemic as well as non-ischemic car-
diomyopathy and recommendations for implantable car-
dioverter defibrillator treatment forprimarypreventionof SCD,
now considered standard of care, are heavily dependent on
levels of EF9e namely left ventricular ejection fraction of35%
in symptomatic patients (II_III) and <30% in post MI patients
with lesser symptoms. It is immediately obvious that ourmajor
guidelines are based on a very crude parameter e EF mea-
surement is highly unreliable with great inter-observer varia-
tion10 and this is even worse in patients with AF or multiple
PVCse both ofwhichare commonandportend SCD.Moreover,
SCD is more common in patients with lesser degrees of LV
dysfunction and those with the lowest EF die more often with
pump failure. Finally, many variables influence arrhythmic
death and EF alone is not as predictive in some studies when
considered alone. In a study by Buxton et al,11 patients with EF
30% without other risk factors had a low mortality risk (2% a
year risk of arrhythmic death, suggesting no ICD benefit in the
majority) while those with EF >30% but with other risk factors
had higher risk of sudden death than some patients with EF
30%. Not surprisingly, reduced ejection fraction per se, has a
low sensitivity and specificity as a risk stratification tool in
identifying patients at risk of SCD.11 Furthermore, most SCD
events (in terms of absolute number of cases) occur in patients
with preserved left ventricular ejection fraction4,9e thus using
EF to stratify for SCDwillmiss amajor portionof subjects prone
toSCD.Currently, CMRremains thebestoption tomeasureEFe
it is highly accurate and reproducible. Radionuclear techniques
are also available for EFmeasurements but suffer frommanyof
the same limitations in patients with abnormal rhythms (e.g.
AF). Major working groups have concluded that while current
methods of clinical risk prediction are inadequate and LV
ejection fraction is effective in only a small subgroup.12 It is
however important to remember that most of the trials
showing benefit in identification and treatment of patients
prone to SCD have used Echo as their main instrument for
measuring EF.
2.2. Myocardial scar
Myocardial scar is often an area where collagen weaves
around islands of varying degree of viable myocytes, and is a
strong substrate for arrhythmogenesis. It creates tissue in-
homogeneity, allows slow conduction and re-entrant currents
that underlie malignant arrhythmias.13 Not surprisingly, risk
of SCD in both IHD and non IHD patients tracks scar burden
and scar tissue heterogeneity measured with cardiac mag-
netic resonance.13,14 Scar can be assessed by any number of
methods including Echo & nuclear imaging studies, but late
gadolinium enhancement on cardiac magnetic resonance
(LGE-CMR) is currently the ‘gold-standard’ in imaging for
myocardial scar.13e15 LGE has been validated to represent
fibrosis and an expansion of extracellular volume in ischemic
as well as non-ischemic heart disease.
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and there is no consensus on the standard method for
myocardial scar quantification. Most predictive CMR tech-
niques, for SCD risk stratification, are based on the fact that the
signal intensity (SI) of an infracted area or fibrotic area (scar)
post Gadolinium (late gadolinium enhancement e LGE) is
higher than that of the normal myocardium. LGE is expressed
as signal intensity and there are variousways of differentiating
abnormal fromnormal. A simple schemauses LGESI>2 SDof a
remote non-involved myocardium, while another used be-
tween 2 and 3 SD, but even higher SD cut off values have also
beenused.15 Peri-infarct gray zoneshavebeendefined variably:
peri-infarct and core-infarct zonesas LGESI between2and3SD
and greater than 3 SD of the reference myocardial segment
respectively or as having SI that is between normal myocar-
dium and <50% of infarct core SI. Scar heterogeneity has also
been studied in non-ischemic cardiomyopathies like HCM,
where one strategy used values 4 SD but <6 SD above the
mean signal intensity of normal myocardium for intermediate
LGE-SI while threshold of 6 SD above normal myocardium
was considered high LGE-SI. Scar has been quantified by
manual orautomated techniques for tracing regionsof interest.
2.3. Abnormal cardiac autonomic activity
Abnormalities in cardiac autonomic activity are considered to
be contributory factors or triggers in SCD. Radiotracers that are
picked up into the cardiac adrenergic synapse, using a mech-
anism similar to catecholamines, are used to measure cardiac
adrenergic activity. 123Iodine-metaiodobenzylguanidine (123I-
MIBG) and 11C-meta-hydroxyephedrine (11C-HED) can be used
for this purpose and have been successful in predicting
adverse outcomes in cardiomyopathies.16
2.4. Identification of structural heart disease
Structural heart disease portends an increased risk for SCD and
imaging provides the best ability to map and characterize car-
diac structure. Thus identification of cardiac structure is often
the first step in triaging for SCD risk; however, while abnormal
structure is predictive of SCD, most of the population-
attributable risk (PAR) of SCD is in subjects without any
knownstructural abnormalities. Thismakes it a less productive
method in general screening for SCD. Both, ventricular viability
and LV dyssynchrony, are associated with increased risk of
ventricular arrhythmias and cardiac resynchronization therapy
(CRT) has been shown to reduce this risk.17,18 Both viability and
dyssynchrony can be best characterized through imaging and
remain targets in the evaluation for SCD However, just as with
structural heart disease in general, its population based efficacy
for screening remains poor.3. Specific imaging modalities in the
evaluation for sudden cardiac death
3.1. Echocardiography
Echocardiography is commonly used in the evaluation of pa-
tients with suspected structural heart disease who presentwith syncope, ventricular arrhythmia, hemodynamic insta-
bility, ischemia/infarction or heart failure. Echocardiography
is an excellent modality for myocardial structure and with its
fast frame rate, for regional and global function. Ventricular
volumes, thickness and mass are surrogates for all adverse
events including arrhythmic death. Scar size, thickness and
viability are measured but other modalities, like CMR, have
replaced echo for this purpose. Echo has a particularly
important role in triaging for SCD in HCM. LV thickness
3.0 cm on echocardiography is an important adverse marker
of outcome.19 Echo studies have also shown that LVmassmay
be more important for SCD than wall thickness.20 Finally, the
pattern of hypertrophy in HCM is a strong determinant of
events. Those with a reversed S shaped HCM have little
outflow obstruction but an association with sarcomeric HCM
and a high arrhythmic event rate with MHY7 mutation.21
Echocardiography, due to its ease of use and widespread
availability, is one of the primary tools used to assess left
ventricular ejection fraction (LVEF). 3D is better for quanti-
fying EF and volumes compared to 2D echo with or without
contrast but most of our SCD data are based on 2D echo in-
formation. Thus, while 3D echo will give us a more accurate
EF, it is not known if this as yet translates to better prediction
of SCD. However, it is important to understand the limitations
of EF measurements. EF prediction shows great inter observer
variability in the verymild and very severe LV dysfunction. For
example, an EF measurement at the ICD guideline cut off can
vary up to  3.3% on 2D study using the Simpson’s formula
and 1.7% on 3D measurement; interval EF measurements
can also change due physiological changes, differences in how
the study was acquired, and interobserver variability e 5e6%
with non contrast 3D and 10e13% with 2D techniques.22 Not
surprisingly, only a minority of patients chosen for ICDs on
the basis of EF cut offs show appropriate shocks on follow up
suggesting that while EF is currently the best practice stan-
dard for triaging for SCD, it remains a very crude and poor
parameter.
LVEF is useful for predicting need for ICD but it is not clear
if this is a property of “reduced contractility” or a reflection of
“degree of injury/scar”. Nevertheless, more precise methods
of regional and global contractility (function), like deformation
imaging (strain, strain rate etc), are being explored to predict
SCD (Fig. 1). Myocardial strain curves quantify regional
myocardial contraction, dispersion and timing, and are better
than EF in predicting LV function as well as ventricular ar-
rhythmias.23 Global longitudinal strain (GLS e the average of
peak negative strain of 16 left ventricular segments greater
than or equal to 12% by speckle tracking) as well as me-
chanical dispersion which is a surrogate of electrical hetero-
geneity in the myocardium (SD of time from the peak of R-
wave on electrocardiography to peak systolic strain in 16 left
ventricular segments) have been found to be an independent
predictor of arrhythmic events in prospective studies in large
numbers of patients following acute myocardial infarc-
tion23,24; this was independent of and better than EF mea-
surement.23 While low LVEF was associated with arrhythmic
events it was not as good in patients with lesser degree of LV
dysfunction while GLS was more predictive for arrhythmic
events than LVEF while remaining useful also in patients with
EF >35%.24 Combining GLS and mechanical dispersion (MD)
Fig. 1 e Deformation imaging and risk of SCD. Top Panel: Normal individuals show little dispersion in peak myocardial
strain timing but abnormal ventricles show significant mechanical dispersion that was prominent in patients with
arrhythmias. Middle Panel: In patients with DCM, Global longitudinal strain and LVEF are reduced in both patients with and
without VT but worse contraction dispersion was seen in a patient with VT. Bottom Panel: Similarly, dispersion is worse in
post MI patients who have arrhythmic events. Modified from Haugaa et al. J Am Coll Cardiol Img 2010;3:247e256; JASE
2012;25,667e673; J Am Coll Cardiol Img 2013;6:2013 841e850.
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early window post MI e traditionally, ICD placement is not
recommended in the first 40 days post MI since a benefit was
not shown. However, there is a significant risk of SCD in this
period. A recent study showed that GLS measured in the very
early post MI period predicted long term SCD better than EF
and other echo parameters. Interestingly, MD was difficult to
evaluate in the peri MI period and failed to show additive
benefit over GLS unlike in the period late after MI.25 GLS thus
might be an important and easily obtainable parameter in
predicting risk in patients early after MI, especially in those
with EF >35% or those with EF <35% but thought to be at low
risk for an arrhythmic event by other current stratification
guidelines.
Dilated cardiomyopathy (DCM) and ischemic cardiomyop-
athy (ICM) have many similar final pathway mechanisms forSCD including scarring and mechano-electrical dys-
synchrony; DCM is associated with SCD and patients with
low EF are recommended for an ICD. Just as in ICM, EF is a poor
predictor of ICD events in DCM and deformation imaging,
which uses multiple segments across the whole cardiac cycle
and is a better reflector of scar heterogeneity, might perform
better. Indeed a recent study26 showed that mechanical
dispersion was a strong predictor of ventricular arrhythmias
in patients with DCM independent of LVEF most likely since
regional myocardial deformation could be a surrogate of
electromechanical interactions.
Mechanical dispersion reflects myocardial contraction
variability, and in turn scar heterogeneity, and has been used
to demonstrate finer abnormalities in syndromes associated
with SCD. Mechanical dispersion is a surrogate of electro-
mechanical dispersion and strain imaging shows increased
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syndrome and predicts adverse arrhythmic outcome better
than QTc alone.27 Arrhythmogenic right ventricular cardio-
myopathy (ARVC) causes SCD in previously healthy young
individuals with and even without obvious signs of RV struc-
tural disease. Traditional diagnosis is based on RV dilatation
and dysfunction but this would not identify asymptomatic
carriers of desmosomal mutations. Mechanical dispersion
heterogeneity and decreased myocardial strain is prominent
in patients with ARVC showing arrhythmias and could be
used for risk stratification of patients as well as asymptomatic
mutation carriers. While MRI is excellent for detecting struc-
tural abnormalities in ARVC, it appears that newer echo
techniques can detect ventricular abnormalities in asymp-
tomaticmutation carriers with normal MRI. In addition its use
in the risk stratification of patients with CAD, global longitu-
dinal strain has a similar role in hypertrophic cardiomyopa-
thy,28 and systemic sclerosis.29 It is important to realize that
while early studies seem to show promise for advanced echo
techniques, including some that seem to show advantage over
EF alone in small studies, none have yet reached a clinical
stage where they can be used for stratification of SCD. For
echo, the ability to measure EF still remains the gold standard
for triaging patients for risk of SCD. Clinical trials using GLS
etc to predict SCD are eagerly awaited.
Athletes, often young, have an excess risk of SCD and this
population most commonly is asymptomatic. Primary preven-
tion is mainly based on screening before participation but the
yield is low and accompanied by a high occurrence of false
negative tests, given low pre test probability in the population.
Multimodality imaging might be useful.30 Echo has been
considered a screening modality in young athletes since it
identifies a different subset (cardiomyopathies like HCM and
ARVC and aortic pathology) than with EKG alone (mainly
channelopathies). Whether Echo should be used at all is
controversial with some sport organizations requiring it even
without robust data. Somehaveadvocatedusing it only in cases
with abnormal EKGs. There is some overlap between physio-
logic hypertrophy in athletes and pathological hypertrophy in
HCM and ventricular remodeling of the RV can overlap with
milder forms of ARVC; thismake the test less specific in a group
with lowpre test probability. Inonescreeningstudy, echo found
suspicious disease in 0.7% of subjects and did not seem to add
much over and above EKG screening.31 Tissue Doppler and
deformation imaging may be marginally better but rigorous
studies with outcomes are lacking.
Other Echocardiographic variables associated with risk of
SCD include increased ventricular thickness and mass,
remodeling [e.g. ratio of septal thickness to left ventricular
diastolic diameter >0.5] and extreme left ventricular hyper-
trophy (30 mm) in hypertrophic cardiomyopathy32 and
increased left ventricular mass index in patients with stable
coronary artery disease. Left atrial size in patients with
chronic heart failure also seems to predict SCD, probably as a
function of the severity of heart failure.
3.2. Nuclear imaging and SCD
Nuclear techniques including most commonly, Single Photon
Emission Computer Tomography Myocardial PerfusionImaging (SPECT-MPI), can predict high risk of cardiovascular
events, including SCD. It provides information beyond EF
measurement on gated studies; it can assess ischemia,
viability and scar tissue that are predictors of death or recur-
rent ventricular arrhythmias.33 Perfusion and scar remain
useful even in SCD events that occur in patients with pre-
served EF. Piccini et al, retrospectively analyzed 4865 patients
with known CAD and EF >35%; summed stress score of >8
predicted increased risk of sudden death34 even after adjust-
ment for EF and relevant clinical factors.
Cardiac Positron Emission Tomography (Cardiac PET)
exquisitely assesses myocardial blood flow, perfusion, func-
tion and metabolism. For example, 82Rubidium PET
myocardial perfusion strongly predicts adverse cardiovas-
cular outcomes.35 However, it is not clear if there is any
unique benefit to using cardiac PET for stratification of pa-
tients at risk of SCD. Nuclear techniques to assess sympa-
thetic activity and sympathetic denervation might have
better success.36 Abnormal uptake and wash out of MIBG, a
compound that mimics neuronal synapse catechol uptake in
the heart, is associated with adverse outcomes, including
SCD, in patients with chronic heart failure. This technique is
becoming readily available and might have a role in triaging
for SCD in patients with known heart disease. Cardiac MIBG
performed better than many traditional techniques used to
stratify risk of SCD (e.g. SAECG, HRV, or QT dispersion) and
remained a powerful predictor of SCD in patients with mild-
to-moderate CHF, independently of LVEF.37 MIBG uptake
predicts VT induction at EP studies38 and appropriate dis-
charges in patients with an ICD.39 Not surprisingly, the
ADMIRE HF study showed that “arrhythmic” events were
significantly more common in subjects with Heart/Medias-
tinum uptake ratio <1.640 Favalito et al studied patients
with ischemic cardiomyopathy eligible for ICD for primary
prevention of SCD.41 In this prospective study, increased
sympathetic denervation, as assessed by 11C-meta-hydrox-
yephedrine PET imaging, predicted SCD independent of
infarct volume and LVEF. Cardiac PET has advantages in
defining inflammation and this may have prognostic poten-
tial in predicting SCD in conditions like cardiac sarcoidosis
where SCD is common and cardiac arrest can be the initial
manifestation even in patients with preserved EF. 18F-fluo-
rodeoxyglucose defects are markers of active disease and
portend poor prognosis and may improve triage for ICDs,
given the currently sub optimal results in these patients.42
Nuclear techniques are thus useful in the risk stratification
for SCD independent of EF but more robust validation studies
are needed. Its role in population screening is likely to be
very limited given the risk of radiation and its inability to
predict SCD with great refinement compared to other rapidly
developing techniques like CMR.
3.3. Cardiac multidetector computed tomography
Cardiac Computed Tomography (Cardiac MDCT) is an excel-
lent modality for ventricular structure and function and can
thus be of help in evaluating patients with substrate for SCD.
A risk of radiation has limited its use but that is changing
given newer technologies that minimize radiation exposure.
While findings on CTA can predict prognosis, there is little
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onary calcium is strongly predictive of adverse events but
whether it can uniquely predict SCD is not clear. CTA’s best
role is in diagnosing coronary artery anomalies.43 However,
these are often causes of SCD in student athletes and radia-
tion is a significant limitation in cost effective screening this
population with CT. Furthermore, it is not known if it adds
more than what we can find with traditional imaging like
Echo. In the young adult athlete, hypertrophic cardiomyop-
athy, congenital coronary abnormalities, channelopathies/
abnormal conduction pathways, aortic rupture, and
arrhythmogenic right-ventricular cardiomyopathy are the
top 5 reasons for SCD and echo can is very useful in at least 3
of these conditions and CTA’s unique abilities may be limited
to coronary anomalies.Fig. 2 e CMR and risk stratification for SCD. The Top Panel sho
hypertrophy (A) and LGE in the septum, especially near RV inse
with severe LVH but a lesser degree of LGE (C). Both severe LVH
Lower Panel: Shows normal heart with no LGE (D, G) and varietie
with mild heterogeneity, while H and I shows varying extent a
septum and this is non viable myocardium. I shows a partial th
might be substrates for arrythmia. Presence of scar and scar he
parameters like EF etc. There is a good-sized LV apical clot (E a3.4. Cardiac magnetic resonance imaging (CMR)
CMR can provide the most comprehensive information about
patients destined for SCD e It is an excellent technique,
probably the gold standard, for morphology (EF, Volume,
Thickness and Mass), and may be even better than nuclear
perfusion studies for inducible ischemia.44 Its main strength,
however, lies in its ability to accurately show viability and scar
in the myocardium (Fig. 2). CMR detected scar is predictive of
SCD in heart failure with both, preserved as well as reduced
EF, ischemic and non-ischemic cardiomyopathy as well as in
syndromes like HCM, ARVC and infiltrative diseases.45 The
extent of LGE on CMR is a strong predictor of ventricular
arrhythmic events. Total scar burden as well as, peri-infarct
scar predicts SCD or ventricular arrhythmias in ICM. Apartws patients with HCM with severe asymmetric septal
rtion (B). No LGE is seen in the other walls. Another HCM
(>30 mm) and extent of LGE predict SCD risk. Middle &
s of scar (E, F, H, I). Apical scar (E) and anterio septal scar (F)
nd thickness e H is a full thickness scar in most of the
ickness scar with islands of tissue that is not scar e these
terogeneity predict arrhythmic events better than current
nd H). LGE- Late Gadolinium Enhancement.
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peri infarct zone and identify the characteristics of the peri
infarct zone (presumably a mixture of dead and living cells
with variable degree of viability and thus an arrhythmogenic
substrate) and the “gray area” zone region, both of which area
strongly associated with arrhythmic events.46 Such gray area
or peri infarct morphology seems to predict arrhythmia and
SCD better than infarct size and EF in the post MI period. Total
scar is also an independent predictor of arrhythmic endpoints
in DCM with mid wall fibrosis, [seen in about a third of pa-
tients with DCM], being an independent predictor of sudden
death and ventricular tachycardia.47 Not surprisingly, a recent
meta-analysis showed that the effect is independent of
reduced LVEF; (about 4 fold increase in risk over patients with
little scar).48 However, most studies in this area involve small
samples and have varying criteria scar quantification and
end-points.
CMR Scar size is the most exciting marker for SCD and but
its unique strength seems to be that it can further stratify
patients with both low and higher EF (group that has the
highest population attributable risk for SCD but who are not
traditionally considered candidates for ICD therapies in cur-
rent guidelines). Klem et al showed the power of CMR in pre-
dicting SCD in this group e patients with LVEF >30% and scar
>5% had more events (death and ICD discharges as well as
SCD) and behaved like those with EF <30%; in contrast, those
with EF 30% and minimal scar (<5%) behaved like patients
with EF >30% in terms of events.45 Scar could thus reclassify
approximately a third of the patients intomore precise groups
better than what an electrophysiologic study could do. It is
likely that such information might be useful in refining who
should get an ICD using criteria over and above EF alone.
CMR is thus a very promising test modality for triaging for
SCD and is likely to get better with time. Having said that, it is
important to recognize that a number of uncertainties remain
that limit its widespread use in regular clinical practice.
Nearly all of the data are from small observational studies e
presence or extent of scar is predictive of more arrhythmia
and arrhythmic deaths; however, there is less data in pro-
spectively studied patients. CMR scar characteristics, like
other stratifying techniques, predict worse outcome as a
group but are not robust enough to predict which particular
individual will have an event and do not identify how soon an
event will occur. It is not clear how much better it would be
than other stratifying techniques (e.g. an EP study, risk scores
or a combination of scoresþ biomarkers). Finally, there are no
intervention studies based on CMR data to prove that the
predictive value is sufficient to make a clinically meaningful
change in practice. Most studies have been in patients with LV
dysfunction and it is not clear how CMR will perform in the
groupwith the highest risk for SCDe thosewithout significant
LV dysfunction in the general population. It is not clearwhat is
the best way to characterize scar size and multiple methods
are in use. It is also not clear which feature of a scar conveys
the highest risk (size, thickness, grayness, viability in scar etc)
and extent of scar needed to predict risk in different subsets
(cut off) is still unclear. Its test performance characteristics
(positive and negative predictive value) are not well known in
many sub groups and cost effectiveness may be suboptimal in
the group with preserved EF (where most of the SCD deathsoccur). Finally, Late Gadolinium Enhancement (LGE) on CMR
may be indicative of overall bad prognosis and not just
arrhythmic death.45
Myocarditis is a special subset of heart failure with variable
recovery and a highmortality that is often due to SCD. LGE has
been shown to be a very powerful predictor of outcome in-
dependent of degree of failure as measured with LV size or
function. In the study by Grun et al, no patient with biopsy
proven myocarditis but without LGE died on follow up; this
was irrespective of LV size and function.49 On the other hand,
the presence of LGE had a 12.8 fold hazard ratio for cardiac
death. Interestingly, LGE did not correlate well with EF or re-
covery of EF suggesting that it had a unique effect on pre-
dicting SCD.
HCM, an autosomal dominant disease with variable
penetrance is the most common cause of SCD in patients <40
years with a risk of about 1% per year. Predicting SCD is
difficult and current approaches use algorithms that pool
multiple risk factors. A multivariable SCD risk score has low
positive predictive value, and CMRmay help refine this. Many
studies have shown that an association of malignant
arrhythmia and SCDwith LGE (total scar, nature of scar and its
extent). Presence of CMR detected myocardial scar was pre-
dictive of inducible sustained ventricular arrhythmias, SCD or
cardiac death.50,51 However, the effect, while better than
many othermarkers, is not in itself strong enough to influence
therapy in the absence of other high-risk features. Scar is
quite common in HCM and the type of scar (tissue heteroge-
neity reflected by regions of intermediate signal intensity of
LGE) might be more predictive of future events in general and
in HCM in particular.46,52,53 A recent meta-analysis showed
the predictive value of CMR for predicting SCD in HCM.50
While this is exciting, it remains a research area not
currently generating a Class I clinical recommendation32 and
we need strong clinical trial data, showing additive value and
better clinical outcomes, to support its use in general Cardiac
practice.32
CMR also has an important role in other cardiomyopa-
thies. It shows RV morphology better than any of the current
imaging modalities and is the imaging modality of choice for
functional and structural assessment of the right ventricle in
a variety of disorders associated with SCD including RV
infarct and Arrhythmogenic Right Ventricular Cardiomyop-
athy (ARVC). ARVC is an important cause of SCD in the young
and athletes.54 Right ventricular LGE predicts increased like-
lihood of inducible sustained ventricular tachycardia in pa-
tientswith ARVC.1,54 Presence of diffuse disease including left
ventricular involvement with CMR, may call for considering
an ICD for primary prevention of SCD.1 Patients with sarcoid
have a significantly higher risk of arrhythmia and SCD and
LGE (sparing the subendocardium) suggests cardiac involve-
ment and increased risk of cardiac death. A recent study
showed that LGE is predictive of death and ICD discharge in
patients with sarcoid.55 This needs to be confirmed in larger
studies before we use LGE decision making for primary pre-
vention of SCD in such patients. Chagas disease is associated
with cardiac involvement and fibrosis that is common in
patients with SCD and may help triage of who will benefit
from ICDs.56 Finally, CMR is being studied in other cardio-
myopathies including infiltrative diseases (amyloidosis,
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 6 1es 7 0S68hemochromatosis) and cardiomyopathies associated with
muscular dystrophies; however, there is limited evidence for
using this in stratification for SCD. CMR, with its exquisite
detail, might be very important to risk stratify athletes but it
is expensive, not easy to do andmay find a place in evaluating
athletes thought to have high risk from other screening mo-
dalities. It certainly is not likely to be a primary screening
tool. In addition, we don’t have good normal data and since
many high-level athletes have spotty LGE we may not be able
to use LGE (scar) as the primary parameter to screen for risk
(unlike in other conditions like cardiomyopathy).574. Conclusion
Identifying subjects who are at risk for SCD and stratifying
them correctly into low or high-risk groups is the holy grail of
Cardiology. SCD is amajor problem and Imaging is an exciting
modality, but it is important to understand that imaging may
not be a panacea even if we had a good screening tool in SCD
imaging. While imaging shows a lot of promise, it is plagued
by the fact thatmost SCD occurs in relatively healthy subjects,
a massive group who would not ordinarily be subjected to
imaging. EF currently is our primary parameter for risk strat-
ification for sudden cardiac death but is a poor marker with
low sensitivity and specificity. Current data shows that so-
phisticated imaging with techniques, mainly CMR, have the
potential to identify novel high-risk markers underlying SCD,
beyond ejection fraction. Imaging seems to further refine risk
in patients with low EF as well as in those with normal EF; this
is a major strength of advanced imaging. Clinical application
has been slow and not fully prime time. It is important to
remember that while promising, imaging techniques
including CMR, have not been tested in rigorous prospective
studies and thus have not as yet replaced EF as the gatekeeper
to ICD implantation. Despite enthusiasm for imaging in pre-
dicting SCD, participation in rigorous clinical trials has been
modest and one major effort could not even enroll enough
patients to be successful.58 It is, however, important to
remember that even though risk stratification and prevention
of sudden death through Imaging may be of value in certain
selected groups, there is currently a lack of powerful tools for
screening of the general population where the majority of
sudden cardiac deaths occur. Rather than be a population-
screening tool, the immediate focus of research in future
imaging studies needs to be the following e (a). Refine the low
EF population e i.e. finding which patients among the current
MADIT II & SCD-HEFT population(s) benefits most from ICDs.
(b). Identifying high-risk subjects in the preserved EF cate-
gories e a group where most of the SCD risk resides. At this
time, at least till we have good clinical trials, sophisticated
imaging might be limited to the groups with the highest risk
(10 yr risk over 20% or more) and those with abnormalities
found on standard screening techniques. Imaging targeting a
combination of ischemia, scar and innervation with or
without biomarker information, might in theory, refine risk
prediction but the cost effectiveness of such a strategy re-
mains to be proven before widespread applicability. Future
advances will help better crystallize the role of Imaging in
patients at risk for SCD.Conflicts of interest
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